Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Terra

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2013
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alphaAmit S Kalgutkar, Danny Chen, Manthena V Varma, et al.
Circulation|April 4, 2022
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70Brian A Bergmark, Nicholas A Marston, Candace R Bramson, et al.
Pharmacogenetics and Genomics|May 15, 2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failureMaximilian T Lobmeyer, Yan Gong, Steven G Terra, et al.
Clinical and Translational Science|March 26, 2018
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinSangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, et al.
Journal of Clinical Lipidology|December 29, 2023
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
European Journal of Preventive Cardiology|March 14, 2024
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trialAndre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
Clinical Pharmacology and Therapeutics|March 1, 2005
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failureSteven G Terra, Daniel F Pauly, Craig R Lee, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 2, 2013
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alphaAmit S Kalgutkar, Danny Chen, Manthena V Varma, et al.
Circulation|April 4, 2022
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70Brian A Bergmark, Nicholas A Marston, Candace R Bramson, et al.
Pharmacogenetics and Genomics|May 15, 2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failureMaximilian T Lobmeyer, Yan Gong, Steven G Terra, et al.
Clinical and Translational Science|March 26, 2018
Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of ErtugliflozinSangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, et al.
Journal of Clinical Lipidology|December 29, 2023
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3Andre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
European Journal of Preventive Cardiology|March 14, 2024
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trialAndre Zimerman, Stephen D Wiviott, Jeong-Gun Park, et al.
Clinical Pharmacology and Therapeutics|March 1, 2005
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failureSteven G Terra, Daniel F Pauly, Craig R Lee, et al.
The Lancet. Infectious Diseases|July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialEdward Weinstein, Roger Paredes, Annie Gardner, et al.
Pageof 6